News|Articles|February 13, 2018

Particulates, Endotoxins, and Bioburden Characterization of Silicone Tubing for Biopharmaceutical Applications

External Link - PTE0218 Dow-Siv F&C pr2f-Web.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

What's Driving Biopharma M&A Strategy in 2026

ByKristin Ciriello Pothier,Zachary Zubulake

June 16th 2026

The FDA Granted Priority Review to Ravulizumab

Implications of FDA Granting Priority Review to AZ's Ravulizumab

ByZachary Zubulake

June 15th 2026

Modern digital illustration depicting supply chain challenges in pharmaceutical and medical logistics with interconnected icons | Image Credit: ©KHAN VECTOR CO. -stock.adobe.com

Digital Standards Aim to Modernize Quality Assurance without Compromising Confidence

ByMichael Levy

June 15th 2026

Karianne Gelinas, Lehigh Valley Economic Development Corporation

Why Eli Lilly Chose Pennsylvania for its $3.5B Facility

ByZachary Zubulake,Karianne Gelinas

June 15th 2026

Abstract luminous DNA molecule. Doctor using tablet and check with analysis chromosome DNA genetic of human on virtual interface. Medicine. Medical science and biotechnology. | Image Credit: ©ipopba -stock.adobe.com

Optimizing Impact for Rare Diseases

ByDavid O’Connell

June 15th 2026

Particulates, Endotoxins, and Bioburden Characterization of Silicone Tubing for Biopharmaceutical Applications

Related Content

What's Driving Biopharma M&A Strategy in 2026

Implications of FDA Granting Priority Review to AZ's Ravulizumab

Digital Standards Aim to Modernize Quality Assurance without Compromising Confidence

Why Eli Lilly Chose Pennsylvania for its $3.5B Facility

Optimizing Impact for Rare Diseases

Trending on Pharmaceutical Technology

Why Eli Lilly Chose Pennsylvania for its $3.5B Facility

Overcoming Fill-Finish Capacity Bottlenecks in Automated Pen Injector Assembly Lines

Optimizing Impact for Rare Diseases

Implications of FDA Granting Priority Review to AZ's Ravulizumab

GSK's Momelotinib Pursues Rare VEXAS Syndrome Indication